Showing 101 - 120 results of 173 for search 'active crohn’s disease.', query time: 0.08s Refine Results
  1. 101

    The Relationship between C-Reactive Protein/Albumin Ratio and Disease Activity in Patients with Inflammatory Bowel Disease by Yi-Han Chen, Li Wang, Shu-Yi Feng, Wei-Min Cai, Xiao-Fu Chen, Zhi-Ming Huang

    Published 2020-01-01
    “…To explore the disease activity, the Mayo score and Crohn disease activity index were used to assess UC and CD patients, respectively. …”
    Get full text
    Article
  2. 102

    Regulated Spatial Distribution of Cyclooxygenases and Lipoxygenases in Crohn's Ulcer

    Published 2006-01-01
    “…We aimed to clarify the role of different arachidonic pathways and the interrelationships between them in Crohn#39;s disease. <emph>Methods</emph>. Seventeen specimens of Crohn's disease dated between 2003/1/1 and 2005/1/1 were collected and underwent immunohistochemical analyses with cylcooxygenase 1, cyclooxygenase 2, 5-lipoxygenase, and 15-lipoxygenase-1 antibodies. …”
    Get full text
    Article
  3. 103

    Regulated Spatial Distribution of Cyclooxygenases and Lipoxygenases in Crohn's Ulcer by Yao Mao, Jian'an Ren, Jieshou Li

    Published 2006-01-01
    “…We aimed to clarify the role of different arachidonic pathways and the interrelationships between them in Crohn's disease. Methods. Seventeen specimens of Crohn's disease dated between 2003/1/1 and 2005/1/1 were collected and underwent immunohistochemical analyses with cylcooxygenase 1, cyclooxygenase 2, 5-lipoxygenase, and 15-lipoxygenase-1 antibodies. …”
    Get full text
    Article
  4. 104

    Health-care resource use and costs associated with inflammatory bowel disease in northwest London: a retrospective linked database study by Zia UI-Haq, Luiz Causin, Tahereh Kamalati, Durgesh Kahol, Trishan Vaikunthanathan, Charlotte Wong, Naila Arebi

    Published 2024-12-01
    “…We compared mean visit numbers and primary and secondary care costs per patient to examine resource use and costs for active disease versus remission. Results We included 7,733 patients (5,872 with ulcerative colitis [UC], 1,427 with Crohn’s disease [CD], and 434 with codes for both [termed IBD-undefined in this study]). …”
    Get full text
    Article
  5. 105

    Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease by C. J. J. Mulder, S. J. Van Den Hazel

    Published 1998-01-01
    “…Dose-comparing studies in Crohn's disease are even more sparse, but the available results indicate higher efficacy at higher dose levels.…”
    Get full text
    Article
  6. 106
  7. 107

    Host-microbe multi-omics and succinotype profiling have prognostic value for future relapse in patients with inflammatory bowel disease by Jill O’Sullivan, Shriram Patel, Gabriel E. Leventhal, Rachel S. Fitzgerald, Emilio J. Laserna-Mendieta, Chloe E. Huseyin, Nina Konstantinidou, Erica Rutherford, Aonghus Lavelle, Karim Dabbagh, Todd Z. DeSantis, Fergus Shanahan, Andriy Temko, Shoko Iwai, Marcus J. Claesson

    Published 2025-12-01
    “…Crohn’s disease (CD) and ulcerative colitis (UC) are chronic relapsing inflammatory bowel disorders (IBD), the pathogenesis of which is uncertain but includes genetic susceptibility factors, immune-mediated tissue injury and environmental influences, most of which appear to act via the gut microbiome. …”
    Get full text
    Article
  8. 108

    STAT3 Genotypic Variant rs744166 and Increased Tyrosine Phosphorylation of STAT3 in IL-23 Responsive Innate Lymphoid Cells during Pathogenesis of Crohn’s Disease by Ying Tang, Sanda A. Tan, Atif Iqbal, Jian Li, Sarah C. Glover

    Published 2019-01-01
    “…Crohn’s disease (CD) results from dysregulated immune responses to gut microbiota in genetically susceptible individuals, affecting multiple areas of the gastrointestinal tract. …”
    Get full text
    Article
  9. 109

    Serum Concentration and Chemotactic Activity of E-selectin (CD62E) in Inflammatory Bowel Disease by B. Vainerc, O. H. Nielsen

    Published 1994-01-01
    “…In ulcerative colitis the median value was 0.46 nM (0.16–0.75), in Crohn’s disease 0.47 nM (0.22–1.24), and in healthy controls 0.34 nM (0.22–0.83). …”
    Get full text
    Article
  10. 110

    Listeria Rhombencephalitis Complicating Anti-TNF Treatment during an Acute Flare of Crohn’s Colitis by L. Stratton, G. R. Caddy

    Published 2016-01-01
    “…Patients with Crohn’s disease often require the use of immunosuppressant drugs to control disease activity. …”
    Get full text
    Article
  11. 111

    Physical activity pattern and its influencing factors among patients with inflammatory bowel disease in East China by Ying Zhou, Feng Xu, Liyan Xu, Huiwei Liu, Xie Zhang

    Published 2024-12-01
    “…Objective To investigate the current level of physical activity (PA) and its influencing factors among patients with inflammatory bowel disease (IBD) in East China.Design Cross-sectional study.Setting Questionnaire survey recruiting from six tertiary referral hospitals in East China between October and December 2023.Participants Patients with Crohn’s disease (CD) or ulcerative colitis (UC) aged 18–65 years without conditions limiting PA engagement.Primary and secondary outcome measures Primary outcomes comprised total PA, PA levels and sedentary time over 1 week. …”
    Get full text
    Article
  12. 112
  13. 113

    Autophagy in Inflammatory Diseases by Alexander J. S. Choi, Stefan W. Ryter

    Published 2011-01-01
    “…Mutations in autophagy-related genes, leading to loss of autophagic function, have been implicated in the pathogenesis of Crohn's disease. Furthermore, autophagy-dependent mechanisms have been proposed in the pathogenesis of several pulmonary diseases that involve inflammation, including cystic fibrosis and pulmonary hypertension. …”
    Get full text
    Article
  14. 114
  15. 115

    Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease by Panu Wetwittayakhlang, Farah Albader, Petra A Golovics, Gustavo Drügg Hahn, Talat Bessissow, Alain Bitton, Waqqas Afif, Gary Wild, Peter L Lakatos

    Published 2021-01-01
    “…Demographics, comorbidities, IBD (type, treatments, pre- and post-COVID-19 clinical activity, biomarkers, and endoscopic activity), and COVID-19-related outcomes (pneumonia, hospitalization, death, and flare of IBD disease) were analyzed. …”
    Get full text
    Article
  16. 116

    The Use of Probiotics in Gastrointestinal Disease by Karen L Madsen

    Published 2001-01-01
    “…A probiotic preparation (VSL#3 - 6 g/day) that uses a combination of three species of Bifidobacterium, four strains of Lactobacillus and one strain of Streptocccus has shown promise in maintaining remission in ulcerative colitis and pouchitis, as well as in preventing the postoperative recurrence of Crohn's disease. The mechanism of action of probiotics may include receptor competition, effects on mucin secretion or probiotic immunomodulation of gut-associated lymphoid tissue. …”
    Get full text
    Article
  17. 117

    Immunopathogenesis of inflammatory bowel diseases by Ye. A. Konovich, I. L. Khalif, M. V. Shapina

    Published 2013-09-01
    “…Innate immunity changes revealed in last years, related to mutations of genes of bacterial structures receptors (NOD2, toll-like receptors, autophagy), cause disorder of endocellular signal processes and pathological activation of cells of adaptive immunodefense of intestinal mucosa and conforming profile of cytokines with development of chronic inflammation which will be mediated: at Crohn's disease – by Th1-and Th17-cells, cytokines IL-12, interferon-γ etc., at ulcerative colitis – by Th2-and NKT-cells, cytokines IL-4 and IL-3 in combination to incompetence of suppressor function of regulatory Т-cells and their cytokines TGF-β (transforming growth factor) and IL-10.Conclusion. …”
    Get full text
    Article
  18. 118

    Treatment of Inflammatory Bowel Disease in Children by D Grant Gall

    Published 1990-01-01
    “…With the development of new delivery systems, the role for 5-ASA in the treatment of small bowel Crohn's disease is under investigation. Prednisone remains the drug of choice in severe ulcerative colitis and active Crohn's disease. …”
    Get full text
    Article
  19. 119

    Fluticasone Propionate in Inflammatory Bowel Disease by Marta Carpani de Kaski, Humphery JF Hodgson

    Published 1990-01-01
    “…In particular, fluitcasone propionate is a fluorinated glucocorticoid, in which systemic side effects are absent or minimal due to its relatively low absorption and rapid first pass metabolism In an open trial in 12 patients with mild and moderately active Crohn's disease, administration of 20 mg fluitcasone propionate orally was associated with a significant fall in the Crohn's disease activity index and improvement in other parameters of inflammation, without change in either plasma cortisol levels or responsiveness to adrenocorticotropic hormone, suggesting that this drug is a promising therapy for Crohn's disease meriting evaluation against conventional corticosteroids.…”
    Get full text
    Article
  20. 120

    Thromboelastography in Patients with Inflammatory Bowel Disease by Yonghua Shen, Liangliang Shi, Juanjuan Zhang, Hao Zhu, Yuling Yao, Zhenqing Liu, Xiaoping Zou, Xiaoqi Zhang

    Published 2020-01-01
    “…This study was conducted to discover novel thrombophilic markers using thromboelastography (TEG) and to evaluate the relation between the predisposing factors and the activity of disease in Chinese patients with Crohn’s disease (CD) and ulcerative colitis (UC). …”
    Get full text
    Article